Publications by authors named "M Friger"
Introduction: Contemporary data regarding the impact of war on cardiovascular disease is scarce. The Israel-Gaza war that erupted on October 7th, 2023, provided a tragic opportunity to explore the effect of war on the epidemiology, characteristics, and management of patients with acute coronary syndrome (ACS) living in areas of active armed conflict.
Methods: All patients admitted with ACS to our medical center, between October 7th, 2023, and January 6th, 2024, were retrospectively included.
Effects of the COVID-19 Lockdown on HbA1c Levels of Ethnic Minorities and Low-income Groups with Type 2 Diabetes in Israel.
J Racial Ethn Health Disparities
December 2024
Aims: To investigate the impact of low socioeconomic status (SES) and/or membership in ethnic minority has on HbA1c before and during the COVID-19 lockdown.
Methods: A retrospective cohort study was conducted between March 2019 and March 2021, based on data from electronic medical records of 17,072 patients with type-2 diabetes, collected by Clalit (Israel's largest health maintenance organization). Low SES was compared to high and ethnic minorities (Arabs and ultra-Orthodox Jews) were compared to the general Israeli population of mostly Jewish, but not ultra-Orthodox, Israeli citizens.
Evaluation of Antivenom Therapy for Middle East Scorpion Envenomations.
Pediatr Emerg Care
January 2025
Introduction: Scorpion envenomation is a leading cause of envenomation in our region. Antivenom has been used successfully to treat the systemic manifestations of envenomations inflicted by toxic scorpions. Toxic scorpions common in our area include Leiurus quinquestriatus , Androctonus australis , and Buthus occitanus .
View Article and Find Full Text PDFArticle Synopsis
- A study aimed to assess the effectiveness and safety of molnupiravir for COVID-19 treatment specifically within the FDA-defined intended-use population (IUP) in Israel.
- The research involved 49,515 patients, matching 3,957 molnupiravir-treated individuals with 19,785 untreated individuals, focusing on hospitalization and mortality rates.
- Results showed that molnupiravir significantly reduced rates of COVID-19-related hospitalizations and all-cause mortality compared to those not treated with the drug.